Form 4: SCYNEXIS CFO Granted 129,833 Restricted Stock Units

SCYNEXIS Chief Financial Officer Ivor Macleod IV was granted 129,833 restricted stock units, increasing his beneficial ownership.

Summary

• Ivor Macleod IV, the Chief Financial Officer of SCYNEXIS INC (SCYX), acquired 129,833 shares of Common Stock.
• The acquisition occurred on January 29, 2026, and was in the form of restricted stock units (RSUs).
• These restricted stock units vest one-third per year over three years, with the vesting period commencing on February 28, 2026.
• The transaction price for these securities was $0.
• Following this transaction, Ivor Macleod IV beneficially owns a total of 398,529 shares of Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with shareholder interests, without indicating any immediate operational or financial shifts.

Positives

• The grant of restricted stock units aligns the Chief Financial Officer's interests with those of shareholders, as the value of his compensation is tied to the company's stock performance.
• The three-year vesting schedule acts as a retention incentive, encouraging the CFO to remain with the company and contribute to its long-term success.

Negatives

• The issuance of new restricted stock units, upon vesting, could lead to a minor dilutive effect on existing shareholders, although this is a standard practice for executive compensation.

Risks

• The value of the restricted stock units is subject to the future market price of SCYNEXIS INC's common stock, meaning the ultimate value realized by the CFO could be lower than the grant-date value if the stock price declines.
• The vesting schedule requires continued employment, and if the CFO departs before full vesting, a portion of the grant may be forfeited.

Future Outlook

The restricted stock units are scheduled to vest over a three-year period, starting February 28, 2026, indicating a long-term incentive structure for the Chief Financial Officer.

Industry Context

StockSavvy.ai notes that restricted stock unit grants are a prevalent form of executive compensation across various industries, particularly in biotechnology, serving to attract, retain, and motivate key management by linking their financial incentives directly to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• StockSavvy.ai observes that RSU grants are a standard compensation practice across the biotech and pharmaceutical sectors, comparable to similar grants at companies like Pfizer or Moderna for executive retention and performance incentives.
• The three-year vesting schedule is a common structure for executive equity awards, aligning with typical long-term incentive plans seen at peer companies in the life sciences industry.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting, but also benefit from increased alignment of management's interests with long-term stock performance.
• Employees (CFO): Receives significant equity compensation, providing a strong incentive for retention and performance.

Next Steps

• The restricted stock units will vest in three equal annual installments, beginning February 28, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant of restricted stock units. While it indicates alignment of management's interests with shareholders and serves as a retention tool, it does not present new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It is a standard insider transaction.

Keywords

SCYNEXIS, SCYX, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, CFO, Beneficial Ownership, Form 4